Skip to content

Observational study of the correlation between the geriatric assessment tools and prognosis of the geriatric patients with hematological malignancy (prospective observational study)

Observational study of the correlation between the geriatric assessment tools and prognosis of the geriatric patients with hematological malignancy (prospective observational study) - Observational study of the correlation between the geriatric assessment tools and prognosis of the geriatric patients with hematological malignancy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000032929
Enrollment
190
Registered
2018-07-01
Start date
2018-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancy

Interventions

None listed

Sponsors

Hitachi general hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 65 years of age or older patients diagnosed with leukemia,malignant lymphoma,myelodysplasia syndrome,multiple myeloma patients who got written informed consent

Exclusion criteria

Exclusion criteria: patients who treat chemotherapy for hematological malignancy

Design outcomes

Primary

MeasureTime frame
2 years survival rate stratified by geriatric assessment tool

Secondary

MeasureTime frame
monthly hospital days stratified by geriatric assessment tool monthly medical costs stratified by geriatric assessment tool decrease rate of the score of EQ-5D-5L in 1,2years stratified by geriatric assessment tool remission rate by treatment intensity stratified by geriatric assessment tool survival rate by treatment intensity stratified by geriatric assessment tool

Countries

Japan

Contacts

Public ContactSuyama Takuya

Hitachi general hospital hematoligy,oncology

sutaku2468@yahoo.co.jp0294231111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026